$ANIP
ANI Pharmaceuticals (ANIP) Insider Trading
ANI Pharmaceuticals, Inc.Small Cap$1.6B
ANI Pharmaceuticals insiders sold $15.7M in the last 12 months, led by Nikhil Lalwani, with no insider purchases.
View trades →
Insiders (12-Month)
12 Insiders
View trades →
Insider Buys (12-Month)
No insider buys
Latest Buy
No open-market buys on record
Politicians (12-Month)
No politician trades
Recent Insider Trades in ANIP
| Type | Insider | Role | Price | Shares | ΔOwn | Value | Filed |
|---|---|---|---|---|---|---|---|
SELL10b5-1 | Carey Stephen P. | SVP & CFO | $72.87 | 2,850 | −1.7% | -$207,680 | Oct 30, '26 |
SELL10b5-1 | Lalwani Nikhil | President & CEO | $71.89 | 5,400 | −1.6% | -$388,206 | Oct 16, '26 |
SELL10b5-1 | Cook Meredith | Sr. VP, General Counsel & Sec. | $73.59 | 500 | −0.7% | -$36,795 | Oct 14, '26 |
SELL10b5-1 | Carey Stephen P. | SVP & CFO | $73.00 | 2,850 | −1.7% | -$208,050 | Sep 30, '26 |
SELL10b5-1 | Lalwani Nikhil | President & CEO | $71.00 | 5,400 | −1.6% | -$383,400 | Sep 16, '26 |
SELL10b5-1 | Thoma Jeanne | Director | $71.53 | 1,000 | −3.6% | -$71,530 | Sep 15, '26 |
SELL10b5-1 | Cook Meredith | Sr. VP, General Counsel & Sec. | $70.79 | 500 | −0.7% | -$35,395 | Sep 15, '26 |
SELL10b5-1 | Carey Stephen P. | SVP & CFO | $72.80 | 2,850 | −1.6% | -$207,480 | Sep 1, '26 |
SELL10b5-1 | Lalwani Nikhil | President & CEO | $74.30 | 5,400 | −1.5% | -$401,220 | Aug 26, '26 |
SELL10b5-1 | Cook Meredith | Sr. VP, General Counsel & Sec. | $75.48 | 500 | −0.7% | -$37,740 | Aug 13, '26 |
SELL | Gutwerg Ori | SVP, Generics | $77.00 | 3,162 | −4.0% | -$243,474 | Aug 12, '26 |
SELL10b5-1 | Carey Stephen P. | SVP & CFO | $81.36 | 2,850 | −1.6% | -$231,876 | Jul 30, '26 |
SELL10b5-1 | Cook Meredith | Sr. VP, General Counsel & Sec. | $81.84 | 500 | −0.6% | -$40,920 | Jul 14, '26 |
SELLOE+Sale10b5-1 | Carey Stephen P. | SVP & CFO | $86.00 | 3,313 | −1.8% | -$284,918 | Jul 7, '26 |
SELL10b5-1 | Carey Stephen P. | SVP & CFO | $84.12 | 2,850 | −1.6% | -$239,742 | Jun 30, '26 |
SELL10b5-1 | Cook Meredith | Sr. VP, General Counsel & Sec. | $82.03 | 500 | −0.6% | -$41,015 | Jun 15, '26 |
SELL10b5-1 | Haughey Thomas | Director | $80.88 | 2,000 | −4.9% | -$161,760 | Jun 11, '26 |
SELLOE+Sale10b5-1 | Carey Stephen P. | SVP & CFO | $80.00 | 3,312 | −1.8% | -$264,960 | Jun 9, '26 |
SELL | Walsh Patrick D | Director | $80.66 | 13,973 | −26.7% | -$1,127,120 | May 14, '26 |
SELL | Rowland Thomas Andrew | SVP, Head - Established Brands | $79.21 | 459 | −1.2% | -$36,357 | May 13, '26 |
SELL | Lalwani Nikhil | President & CEO | $77.57 | 55,000 | −13.6% | -$4,266,350 | May 13, '26 |
SELL | Gutwerg Ori | SVP, Generics | $79.50 | 2,772 | −3.4% | -$220,374 | May 13, '26 |
SELL10b5-1 | Cook Meredith | Sr. VP, General Counsel & Sec. | $78.16 | 500 | −0.6% | -$39,080 | May 13, '26 |
SELL10b5-1 | Cook Meredith | Sr. VP, General Counsel & Sec. | $77.95 | 500 | −0.6% | -$38,975 | Apr 13, '26 |
SELL | Rowland Thomas Andrew | SVP, Head - Established Brands | $74.91 | 4,772 | −11.0% | -$357,471 | Mar 13, '26 |
SELL10b5-1 | Mutz Christopher | Head of Rare Disease | $71.64 | 3,162 | −3.3% | -$226,526 | Mar 13, '26 |
SELL10b5-1 | Cook Meredith | Sr. VP, General Counsel & Sec. | $72.62 | 500 | −0.6% | -$36,310 | Mar 13, '26 |
SELL10b5-1 | Mutz Christopher | Head of Rare Disease | $74.19 | 5,723 | −5.7% | -$424,617 | Mar 10, '26 |
SELL10b5-1 | Davis Krista | SVP, Chief HR Officer | $74.33 | 6,572 | −11.2% | -$488,474 | Mar 10, '26 |
SELLOE+Sale | Carey Stephen P. | SVP & CFO | $75.50 | 7,312 | −3.8% | -$552,031 | Mar 5, '26 |
SELL10b5-1 | Mutz Christopher | Head of Rare Disease | $74.00 | 417 | −0.4% | -$30,858 | Mar 4, '26 |
SELL | Gutwerg Ori | SVP, Generics | $76.50 | 2,060 | −2.4% | -$157,590 | Mar 4, '26 |
SELL | Walsh Patrick D | Director | $74.23 | 6,000 | −10.3% | -$445,380 | Mar 3, '26 |
SELL10b5-1 | Mutz Christopher | Head of Rare Disease | $78.02 | 5,323 | −5.9% | -$415,300 | Feb 23, '26 |
SELL10b5-1 | Davis Krista | SVP, Chief HR Officer | $77.74 | 3,814 | −7.2% | -$296,495 | Feb 23, '26 |
SELL10b5-1 | Mutz Christopher | Head of Rare Disease | $76.55 | 7,032 | −7.2% | -$538,300 | Feb 17, '26 |
SELL10b5-1 | Cook Meredith | Sr. VP, General Counsel & Sec. | $76.80 | 500 | −0.7% | -$38,400 | Feb 17, '26 |
SELL10b5-1 | Cook Meredith | Sr. VP, General Counsel & Sec. | $84.33 | 500 | −0.7% | -$42,165 | Jan 14, '26 |
SELL10b5-1 | Davis Krista | SVP, Chief HR Officer | $82.40 | 1,622 | −2.7% | -$133,653 | Dec 19, '25 |
SELL10b5-1 | Cook Meredith | Sr. VP, General Counsel & Sec. | $82.32 | 400 | −0.5% | -$32,928 | Dec 12, '25 |
SELL | Tannenbaum Renee P | Director | $81.15 | 1,800 | −6.7% | -$146,070 | Dec 9, '25 |
SELL | Walsh Patrick D | Director | $86.88 | 8,643 | −12.9% | -$750,904 | Nov 17, '25 |
SELL10b5-1 | Cook Meredith | Sr. VP, General Counsel & Sec. | $87.27 | 400 | −0.5% | -$34,908 | Nov 14, '25 |
SELL | Gassert Chad | SVP - Corp. Dev. & Strategy | $89.06 | 14,736 | −6.0% | -$1,312,435 | Nov 14, '25 |
Older than 12 months | |||||||
SELL10b5-1 | Cook Meredith | Sr. VP, General Counsel & Sec. | $90.09 | 400 | −0.5% | -$36,036 | Oct 14, '25 |
SELL10b5-1 | Davis Krista | SVP, Chief HR Officer | $98.04 | 1,000 | −1.6% | -$98,040 | Sep 22, '25 |
SELL10b5-1 | Cook Meredith | Sr. VP, General Counsel & Sec. | $98.42 | 400 | −0.5% | -$39,368 | Sep 15, '25 |
SELL | Pera Antonio R | Director | $94.94 | 7,292 | −24.3% | -$692,302 | Sep 4, '25 |
SELL | Leonard Matthew J | Director | $90.62 | 2,528 | −26.9% | -$229,087 | Aug 26, '25 |
SELL | Davis Krista | SVP, Chief HR Officer | $91.10 | 1,763 | −2.7% | -$160,609 | Aug 25, '25 |
SELL | Shanmugam Muthusamy | Head of R&D, COO-Novitium Ops | $90.36 | 100,000 | −15.9% | -$9,036,008 | Aug 22, '25 |
SELL | Thoma Jeanne | Director | $89.15 | 21,540 | −47.9% | -$1,920,370 | Aug 20, '25 |
SELL | Pera Antonio R | Director | $89.73 | 5,421 | −15.3% | -$486,426 | Aug 20, '25 |
SELL | Leonard Matthew J | Director | $88.17 | 6,937 | −42.5% | -$611,635 | Aug 18, '25 |
SELL | Walsh Patrick D | Director | $89.05 | 9,000 | −11.4% | -$801,450 | Aug 18, '25 |
SELL | Shanmugam Muthusamy | Head of R&D, COO-Novitium Ops | $88.25 | 100,000 | −13.7% | -$8,824,533 | Aug 18, '25 |
SELL | Gassert Chad | SVP - Corp. Dev. & Strategy | $86.97 | 20,000 | −7.5% | -$1,739,400 | Aug 18, '25 |
SELL | Rowland Thomas Andrew | SVP, Head - Established Brands | $85.71 | 4,975 | −10.9% | -$426,407 | Aug 14, '25 |
SELL | Lalwani Nikhil | President & CEO | $85.93 | 56,960 | −12.2% | -$4,894,573 | Aug 14, '25 |
SELL | Gutwerg Ori | SVP, Generics | $86.53 | 5,873 | −6.5% | -$508,191 | Aug 14, '25 |
SELL10b5-1 | Cook Meredith | Sr. VP, General Counsel & Sec. | $88.87 | 400 | −0.5% | -$35,548 | Aug 14, '25 |
SELLOE+Sale | Carey Stephen P. | SVP & CFO | $86.07 | 50,000 | −21.7% | -$4,303,500 | Aug 14, '25 |
SELL | Haughey Thomas | Director | $85.93 | 19,341 | −34.6% | -$1,661,972 | Aug 14, '25 |